5/6/2025

Comprehensive Analysis

• Earnings Beat Amid Guidance Cut: Zimmer Biomet (ZBH) reported Q1 2025 adjusted EPS of $1.81 (beating estimates by 2.26%) and revenue of $1.91B (surpassing forecasts by 0.72%). However, FY2025 adjusted EPS guidance was reduced to $7.90–$8.10 (from $8.15–$8.35), citing tariff uncertainty and Paragon 28 integration costs. This duality reflects short-term operational strength but long-term margin compression risks.
• Tariff and Acquisition-Driven Margin Pressure: Management explicitly linked the guidance reduction to global tariff volatility and $1.2B Paragon 28 acquisition costs. Tariffs in key markets like China and the EU threaten supply chain efficiency, while the acquisition’s upfront expenses dilute near-term EPS. Social media debates whether the move will drive long-term value or strain margins.